Skip to content
Stay curious ↗

Follow your curiosity.

Try “brain”, “genomics”, or another subject you follow.

Today/Diagnostics
Diagnostics · The big question

Current Methods for Diagnosing Brain Trauma in Athletes Fall Short

Performance of traumatic encephalopathy syndrome criteria in identifying individuals with chronic traumatic encephalopathy

Nature Medicine1 min readAI-assisted summary
Editorial illustration for Performance of traumatic encephalopathy syndrome criteria in identifying individuals with chronic traumatic encephalopathy
Editorial illustration

Summary

For years, the medical community has sought ways to identify chronic traumatic encephalopathy, a degenerative brain disease linked to repeated head impacts, in living patients. Doctors currently look for a specific group of symptoms known as traumatic encephalopathy syndrome to estimate if an athlete has underlying brain damage. However, new research suggests this evaluation method is highly unreliable.

A recent study published in Nature Medicine reveals that the proposed clinical features used to diagnose this syndrome are poor predictors of actual brain pathology. Simply put, the behavioral and cognitive symptoms doctors look for do not accurately match the physical signs of the disease in the brain.

Because these clinical features have such a low predictive value, researchers warn that relying on them carries a significant risk of misdiagnosis. It is worth noting that the initial abstract does not share specific sample sizes, statistical parameters, or patient demographics, making it difficult to quantify exactly how often these errors occur. Still, the core finding points to a major flaw in how doctors currently evaluate former athletes for brain trauma.

Why it matters.

The findings are critical because receiving an incorrect diagnosis of a progressive brain disease can have a profound impact on a former athlete. If the current diagnostic criteria are unreliable, patients might be told they have a severe neurodegenerative condition when they do not. This could cause immense distress and lead to improper medical management.

For the sports medicine industry, this research underscores an urgent need to develop more accurate diagnostic tools. The study clearly demonstrates that relying solely on observed clinical symptoms is not enough to accurately identify chronic traumatic encephalopathy. Moving forward, researchers and doctors will need to find more precise methods to evaluate neurodegeneration in living athletes to ensure they receive the correct care.

Keep the context

Follow the evidence.

This AI-assisted summary is a starting point. Read the original reporting for its methods, scope, and limitations.

Your next discovery.

Keep exploring ↗
Diagnostics

Routine PSA Tests Likely Save Lives, Updated Study Finds

Prostate cancer screening has long been a subject of debate among medical professionals. Doctors commonly use a blood test called the prostate-specific antigen, or PSA, test to look for early signs of the disease. A massive new review of clinical trials has updated our understanding of how well this test works. The findings suggest that relying on the PSA test alone likely reduces the number of men who die specifically from prostate cancer, and it might even reduce overall death rates compared to not screening at all. Routine screening naturally leads to a spike in prostate cancer diagnoses, particularly cases that are localized, meaning the cancer has not spread beyond the prostate gland. However, catching these early cases appears to have a protective effect later on. The data shows routine screening could potentially reduce the number of aggressive, metastatic cancers that eventually spread to other parts of the body. The researchers also looked at a newer screening approach that combines the traditional PSA blood test with a special protein panel, called a kallikrein test, and an MRI scan. So far, early evidence suggests this advanced combination has little to no impact on the number of cancer diagnoses compared to no screening, though it is still too soon to know exactly how it affects long-term survival rates.

PubMed2 min read
Diagnostics

Simple AI Uses DNA to Accurately Classify Dozens of Cancers

Machine learning is often hyped in modern medicine, but highly complex algorithms that look flawless in the lab frequently fail in the real world. To solve this, scientists have developed a new artificial intelligence framework that takes a simpler, more reliable approach to diagnosing cancer. By analyzing DNA methylation, which are chemical tags that attach to DNA and influence how genes behave, researchers created a tool capable of classifying dozens of different cancers and healthy tissues with impressive precision. The research team trained their system using a massive dataset of over 10,000 tissue samples. Surprisingly, they found that a straightforward algorithm called logistic regression actually outperformed highly complex deep neural networks. By looking at 1,208 specific chemical markers on the DNA, their simple model achieved a 90 percent accuracy rate in distinguishing between 54 different healthy and cancerous tissue types. When tested on central nervous system tumors, the tool successfully identified 59 different subtypes with an outstanding 94 percent accuracy. To ensure these results were reliable, the team put their methodology to the test using an independent dataset of over 2,300 samples gathered from 28 different studies. They also introduced a special filtering technique to catch and remove abnormal biological data, which further boosted the model's overall performance and helped prevent artificially inflated success rates.

PubMed2 min read
Diagnostics

Targeted Scan Shows Promise in Ruling Out Breast Cancer False Alarms

When doctors screen for breast cancer, they sometimes find suspicious areas that do not look like traditional lumps. These are known as non-mass enhancements. To figure out if these unusual spots are dangerous, medical teams often use magnetic resonance imaging (MRI) or an advanced x-ray called contrast-enhanced spectral mammography (CESM). However, these conventional scans can sometimes be overly sensitive. They frequently flag harmless tissue as suspicious, leaving doctors uncertain and patients worried. A recent study investigated what happens when an additional technology, called positron emission mammography (PEM), is added to the diagnostic process. PEM is a specialized scan that detects areas of high cellular activity, which is a common feature of cancer. Researchers reviewed the medical records of 108 women who had these unclear spots on their initial scans. Half of the women had their PEM scans reviewed alongside an MRI, while the other half had their PEM scans paired with a CESM scan. The addition of PEM dramatically improved the accuracy of the diagnoses. When paired with an MRI, the PEM scan correctly identified all the cancers while boosting the ability to accurately rule out harmless spots to 100 percent, a massive improvement from the 30 percent accuracy of MRI alone. A similar improvement was seen when PEM was paired with CESM. Additionally, different radiologists looking at the PEM scans agreed with each other much more often than they did when reviewing the other types of imaging. Out of 30 highly unclear cases that ultimately turned out to be completely harmless, the PEM scan correctly recognized 29 of them.

PubMed2 min read

A little science goes a long way.

Clear, thoughtful biotech briefings. In your inbox three times a week.

Stay curious. Subscribe free ↗
Current Methods for Diagnosing Brain Trauma in Athletes Fall Short — Daily Strand